Forian Inc 2026年季度报告

FORIAN INC. Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file Indicate by check mark whether the registrant has submitted electronically; every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.0405 of this chapter) during the preceding 12 months (or for such shorter Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ PART IFINANCIAL INFORMATION Note 1BUSINESS ORGANIZATION AND NATURE OF OPERATIONS Forian Inc. (the “Company” or “Forian”) was incorporated in Delaware on October 15, 2020 as a wholly owned subsidiary ofForian LLC (f/k/a Medical Outcomes Research Analytics, LLC) (“MOR”) for the purpose of effecting the business combination withHelix Technologies, Inc. (“Helix”). Forian provides a unique suite of data management capabilities and proprietary information and On January 8, 2026, at a special meeting of stockholders (the “Special Meeting”) of Forian, Inc., the stockholders of theCompany approved a proposal to redomicile through a statutory conversion (the “Redomiciliation”) the Company from a corporationorganized under the laws of the State of Delaware (the “Delaware Corporation”) to a corporation organized under the laws of the State On October 31, 2024, (the “Kyber Acquisition Date”), the Company entered into a Membership Interest AssignmentAgreement (the “Assignment Agreement”), by and among Cowen Inc. (“Cowen”), IMcK Holdings LLC (“Minority Seller” andtogether with Cowen, the “Sellers”), Kyber Data Science, LLC (“Kyber”) and the Company, pursuant to which the Company acquiredall outstanding equity interests of Kyber (the “Kyber Transferred Interests”) from the Sellers, effective October 31, 2024 (the “KyberTransaction”). The business combination with Kyber was accounted for using the acquisition method of accounting in accordance with Note 2BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accountingprinciples generally accepted in the United States of America (“U.S. GAAP”). Certain footnotes and other financial informationnormally required by U.S. GAAP have been condensed or omitted in accordance with instructions to Form 10-Q and Article 8 ofRegulation S-X. In the opinion of management, such statements include all adjustments which are considered necessary for a fairpresentation of the unaudited condensed consolidated financial statements of the Company as of March 31, 2026. The operating results Note 3SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of (i) Forian LLC (f/k/aMedical Outcomes Research Analytics, LLC); (ii) Kyber Data Science LLC and its wholly owned subsidiaries Kyber Aesthetic DataLLC (which merged into Kyber Data Science LLC on June 19, 2025), Kyber Data Sub LLC, Kyber Health Data LLC and KyberSurvey Data LLC (which merged into Kyber Data Science LLC on June 19, 2025) (effective October 31, 2024) and (iii) HelixTechnologies, Inc. and its wholly owned subsidiaries Helix Legacy, Inc. (f/k/a Security Grade Protective Services, Ltd.), and Green Table of Contents Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements andassumptions that affect the reported amounts of assets, liabilities, revenues and expenses together with amounts disclosed in the relatednotes to the financial statements. The significant areas of estimation include but are not limited to revenues, accounting for theallowance for credit losses, income taxes and stock-based compensation. Certain of the Company’s estimates could be affected by Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820,Fair ValueMeasurements and Disclosures(“ASC 820”), which defines fair value, establishes a framework for measuring fair value and expands ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exitprice) in the principal or most advantageous market for the asset or liability in an ordinary transaction between market participants onthe measurement date. ASC 820 also establishes a fair value hiera